Literature DB >> 1330845

Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection.

F Cassani1, L Muratori, P Manotti, M Lenzi, M Fusconi, G Ballardini, L Selleri, U Volta, D Zauli, R Miniero.   

Abstract

Antinuclear antibodies with the homogeneous pattern (ANA-H) and smooth muscle antibodies with antiactin specificity (SMA-AA) are regarded as the serum markers of type-1 autoimmune chronic hepatitis. Their diagnostic relevance, however, has been questioned recently after the detection of signs of hepatitis C virus infection in autoimmune chronic hepatitis patients. To further evaluate this point, antihepatitis C virus antibodies were sought by two second generation assays (ELISA 2 and RIBA 2) in 100 Italian patients with chronic liver disease of unknown aetiology, including 46 with (autoimmune chronic hepatitis) and 54 without the above antibodies (cryptogenic). By ELISA 2, antihepatitis C virus, although significantly prevalent in cryptogenic (83%), were found also in a substantial proportion of autoimmune chronic hepatitis patients (46%) (p < 0.0001), their occurrence was confirmed by RIBA 2 in almost all cases (96% and 86%, respectively). Autoimmune patients with either ANA-H or SMA-AA exhibited similar antihepatitis C virus prevalences (59% and 52%, respectively); by contrast, the eight cases positive for both the autoantibodies were consistently antihepatitis C virus negative. These findings confirm that in countries with high hepatitis C virus circulation (like Italy) an overlap between autoimmune chronic hepatitis and hepatitis C virus infection, reflected by 'true' antihepatitis C virus antibodies, does occur. The detection of ANA-H or SMA-AA, in fact, identifies chronic liver disease patients with a relatively low prevalence of antihepatitis C virus, but does not exclude hepatitis C virus infection. Positive findings for both ANA-H and SMA-AA, however, is an appropriate marker for hepatitis C virus free 'primary' autoimmune chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330845      PMCID: PMC1379498          DOI: 10.1136/gut.33.9.1260

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Anti-HCV antibodies detected by ELISA in autoimmune and cryptogenic chronic liver disease.

Authors:  F Cassani; G Ballardini; M Fusconi; M Lenzi; U Volta; D Zauli; F B Bianchi
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

2.  Precipitating antibodies to rabbit thymus extractable antigens in chronic liver disease: relationship with anti-actin antibodies.

Authors:  F Cassani; M Fusconi; F B Bianchi; L Selleri; L Baffoni; M Lenzi; E Pisi
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

Review 3.  Immunological aspects of chronic active hepatitis.

Authors:  I R Mackay
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

4.  Segregation of autoantibody to cytoskeletal filaments, actin and intermediate filaments with two types of chronic active hepatitis.

Authors:  J S Pedersen; B H Toh; I R Mackay; B D Tait; I D Gust; A Kastelan; N Hadzic
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

5.  Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity.

Authors:  M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Immunomorphological characterisation of antinuclear antibodies in chronic liver disease.

Authors:  F Cassani; F B Bianchi; M Lenzi; U Volta; E Pisi
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Absence of autoimmune serological reactions in chronic non A, non B viral hepatitis.

Authors:  I R Mackay; I H Frazer; B H Toh; J S Pedersen; H J Alter
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

10.  Type 2 autoimmune hepatitis and hepatitis C virus infection.

Authors:  M Lenzi; G Ballardini; M Fusconi; F Cassani; L Selleri; U Volta; D Zauli; F B Bianchi
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  12 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

3.  High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.

Authors:  Giovanni Squadrito; Marcello Previti; Marco Lenzi; Enrico Pagano Le Rose; Gaia Caccamo; Tea Restuccia; Enrico Di Cesare; Teresa Pollicino; Giovanni Raimondo
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

4.  Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact?

Authors:  B P Rowan; A Smith; D Gleeson; L P Hunt; T W Warnes
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

5.  Impact of international autoimmune hepatitis group scoring system in definition of autoimmune hepatitis. An Italian experience.

Authors:  F B Bianchi; F Cassani; M Lenzi; G Ballardini; L Muratori; F Giostra; D Zauli
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

6.  Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population.

Authors:  P Muratori; L Muratori; T Stroffolini; G Pappas; P Terlizzi; R Ferrari; S Loffreda; F Cassani; M Rapicetta; V Guadagnino; F B Bianchi; M Lenzi
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

7.  Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

Review 8.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

9.  Non-organ-specific autoantibodies in Indian patients with chronic liver disease.

Authors:  Sunilbaran Daschakraborty; Amita Aggarwal; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2012-09-01

10.  Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.

Authors:  A J Czaja; S Magrin; C Fabiano; G Fiorentino; O Diquattro; A Craxi; L Pagliaro
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.